Novartis data shows overactive bladder therapy Enablex does not impair memory function

By Elaine Rigoli

Tampa, Fla., May 23 - Novartis Pharmaceuticals Corp. said data from a head-to-head clinical study looking at the effects of two prescription medications used to treat overactive bladder showed that treatment with Enablex (darifenacin) did not result in impaired memory function in healthy adults age 60 and older.

In contrast, treatment with Ditropan XL (oxybutynin extended-release or ER), the other medication evaluated in the study, caused significant memory deterioration, the company said in a news release.

Further, the individuals receiving oxybutynin ER failed to notice the change in their memory function, the release said.

Enablex and Ditropan XL are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Both therapies are antimuscarinic agents, meaning they act on muscarinic receptors in the body associated with bladder control, the release said.

These data are analyses of results from a multi-center, randomized, double-blind, placebo-controlled, parallel-group, three-week study involving 150 healthy older adults.

Located in East Hanover, N.J., Novartis develops prescription drugs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.